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fimitations  of  evidence-based  m
oday,  EBM  is  the  gold  standard  for  validating  treatments  and
s  transforming  medicine  into  a  scientiﬁc  discipline.1 Despite
thical  and  logistical  considerations  associated  with  placebo
ontrols,2 there  is  an  ever-growing  reliance  on  randomized
ouble-blind  placebo-controlled  (RDBPC)  trials  over  obser-
ational  studies  and  case  series.  However,  the  fact  that  EBM
uggests  that  RDBPC  trials  are  necessary  for  high  quality
reatment  recommendations,  whereas  observational  stud-
es  and  case  series  receive  only  low  quality  ratings,  merits
urther  scrutiny.3--5
Sackett  et  al.  deﬁne  EBM  as,  ‘‘the  conscientious,  explicit,
nd  judicious  use  of  current  best  evidence  in  making  deci-
ions  about  the  care  of  individual  patients.’’5 Thus,  even  if
 cited  treatment  is  unsupported  by  a  placebo-controlled
rial  but  is  still  the  ‘‘best  available  evidence,’’  then  the
reatment  would  still  be  supported  by  EBM.  Unfortunately,
ackett  and  the  Cochrane  group  go  on  to  classify  ‘‘no  con-
rols,  case-series  only’’  as  Level  V  evidence  that  ‘‘.  .  .contain
seful  information  about  clinical  course  and  prognosis  but
an  only  hint  at  efﬁcacy.’’4 They  further  describe  the  quality
f  this  evidence  as  low.3 This  can  lead  to  errors  of  interpre-
ation  by  clinicians  who,  at  least  in  the  ﬁeld  of  pulmonary
edicine,  often  justify  their  overlooking  of  new,  beneﬁ-
ial,  and  even  life-saving  approaches  because  they  do  not
onsider  the  evidence  supporting  them  to  be  high  quality.
Interventions  that  replace  the  function  of  a  vital  organ
or,  for  that  matter,  any  organ)  cannot  be  placebo  con-
rolled.  Such  interventions  can  only  be  compared  for
econdary  beneﬁts  or  for  their  capacity  to  more  effec-
ively  normalize  physiological  parameters.  For  instance,
 Over 100,000 British sailors died from scurvy between 1500 and
850 despite the fact that James Lind performed a prospective
lacebo-controlled clinical trial in 1747, which demonstrated that
rovisioning ships with citrus fruit could prevent disease. In 1753,
ind published a 400-page evidence-based medicine (EBM) ‘‘A Trea-
ise of the Scurvy,’’ but British doctors could not fathom how lemons
ight affect humoral imbalance, the prevailing paradigm of that
ra. As a result, the British College of Physicians ignored Lind’s
ndings and instructed the Admiralty to carry sulfuric acid solutions
ather than fruit, and for the next 40 years, British sailors continued
o die of scurvy.
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lthough  invasive  continuous  tracheostomy  mechanical  ven-
ilation  and  continuous  noninvasive  ventilatory  support
CNVS)  cohorts  can  be  compared  to  each  other  for  secondary
eneﬁts  and  untoward  effects,  in  the  absence  of  measurable
ital  capacity  (VC),  they  cannot  be  matched  with  placebo
ontrols  any  more  than  can  parachute  use  be  studied  in  this
anner  for  skydivers.6
Prolongation  of  survival  by  CNVS  for  patients  with
uchenne  muscular  dystrophy  and  ‘‘.  .  .a mean  [VC  of]
76  ±  102  mL,  or  3%  of  predicted  normal,  which  is  not
ompatible  with  survival  without  continuous  ventilator  sup-
ort,’’7 has  been  known  since  1979.8 The  same  has  been
eported  for  amyotrophic  lateral  sclerosis  patients  with  VCs
s  low  as  unmeasurable9 and  other  neuromuscular  disease
opulations  with  less  than  2%  of  normal  VC.  Submissions  of
hese  papers  consistently  draw  comments  from  reviewers
hat  there  was  no  control  group,  so  nothing  can  be  general-
zed  from  them.  Reviewers  have  gone  so  far  as  to  state  that
rolongation  of  life  by  a few  months  with  use  of  sleep-only
i-level  positive  airway  pressure  that  has  been  documented
y  controlled  studies  is  high  quality  evidence,  but  prolong-
ng  life  by  as  much  as  60  years  with  CNVS  is  not  because
here  were  no  controls.
Placebo  controls  also  cannot  be  used  when  substituting
or  or  restoring  the  function  of  any  organ  unless  the  interven-
ion  is  so  minimally  effective  that  it  is  difﬁcult  to  determine
ny  positive  treatment  effect  at  all.  For  example,  placebo  is
ot  possible  and  controlled  trials  were  never  performed  for
ialysis  or  renal  organ  transplantation,  mechanical  ventila-
or  support,  cochlear  implants  or  hearing  aids,  prosthetic
egs  or  arms,  hip  and  knee  replacements,  or  parachutes  in
he  absence  of  wings.6 Remarkably,  this  stark  limitation  has
et  to  be  considered  in  the  literature.
Besides  mechanical  ventilation,  expiratory  muscles  must
e  supported  or  substituted  for  by  alternately  applying  pos-
tive  and  negative  pressures  to  the  airways  to  generate
ffective  cough  ﬂows  to  prevent  episodes  of  acute  respi-
atory  failure,  and  if  one  is  intubated,  to  avoid  extubation
ailure.  In  this  manner,  mechanical  insufﬂation-exsufﬂation
MIE)  expulses  airway  debris.  While  the  cough-enhancing
ffectiveness  of  different  devices  and  techniques  can  be
ompared,  such  interventions  cannot  ethically  be  placebo
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controlled;  yet,  intensivists  are  reticent  to  use  MIE,
despite  high  rates  of  extubation  failure  in  many  patient
populations.10 Scrupulous  adherence  to  Cochrane  EBM  crite-
ria  can,  and  do,  result  in  studies11 being  discredited.
Consequently,  acute  respiratory  failure  and  resort  to  tra-
cheotomy  occur  because  there  are  no  ‘‘high  quality’’  RDBPC
studies  of  CNVS  or  MIE.
Modern  medicine  evolves  by  minor  EBM-supported
improvements  on  major  breakthroughs.  As  EBM  establishes
the  efﬁcacy  and  safety  of  new  approaches,  it  is  nonetheless
crucial  to  understand  its  limitations.  As  long  as  there  exists
an  expectation  that  all  innovations  be  grounded  in  RDBPC
trials,  the  institution  of  life-saving  innovations  may  remain
unsubstantiated.  Sackett  supports  the  use  of  both  individual
clinical  expertise  and  best  available  evidence  as  ‘‘evidence-
based,’’  but  too  many  tend  to  forget  this.5 Indeed,  some
medical  journals  offer  free  publication  of  the  latter  but  not
for  observational  studies.
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